Ind-Swift Laboratories Limited share price

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calc…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: INDSWFTLABISIN INE915B01019

16 Oct 2026, 3:29 PM IST₹359.25▲ 1.30 (0.36%)

Market Cap₹ 3,174 Cr.
Current Price₹ 359.25
High / Low₹ 425 / 87
Stock P/E53.7
Book Value₹ 166
Dividend Yield0.00 %
ROCE3.6 %
ROE3.40 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 6.69
Price / Book2.17
OPM-0.8 %
Debt / Equity0.01
Sales growth (5Y)-3.8 %
Profit growth (5Y)—
Promoter holding66.0 %
EV / EBITDA38.3
Beta0.79
All-time high₹ 425

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
INDSWFTLAB	-1.28%	+53.60%	+147.06%	+307.54%	+243.42%	+57.58%	+41.84%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Ind-Swift Laboratories Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹3,174 crore.
It trades at 53.7 times its last 12 months' earnings and 2.2 times book value.
Revenue grew -3.8% a year over the last 5 years.
Return on equity was 3.4% and return on capital employed 3.6% in the latest year.
Debt was 0.01 times shareholders' equity.
The share price is 15.4% below its 52-week high and up 243.4% over one year.
Promoters and insiders hold about 66.0%; institutions about 6.3%.

Pros

Strong return on equity: 33.6% on average over the last 3 years.
Company is almost debt-free (debt is 0.01 times equity).
Latest quarter (Jun 2026): sales up 25% and profit up 181% from a year ago.

Cons

Sales growth has been slow: -3.8% a year over the last 5 years.
Profit growth has been weak: -4.5% a year over the last 3 years.
Other income makes up 78% of profit before tax.
Trades at 53.7 times earnings, above its 3-year median of 3.1.
Institutional (FII + DII) holding has fallen by 8.1 points over 3 years.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Ind-Swift Laboratories Limited

Employees: 1,388
Head office: Manimajra

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Ind-Swift Laboratories	359.25	53.7	3,174	0.00	25	181.32	191	25.35	3.6	3.4	2.17	-0.8	0.01	66.04	641	-3.8
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	786	-39.18	7,119	2.33	14.9	11.8	3.11	17.5	0.02	31.13	28,163	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 56 Co.	1,712.85	34.1	14,445	0.21	680	21.70	6,020	18.81	14.6	13.4	4.01	15.4	0.21	55.20	20,499	11.0

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	310	290	288	393	33	12	9	138	153	153	151	170	191
YOY Sales Growth %	10.77%	-6.61%	-8.05%	29.28%	-89.31%	-95.87%	-96.99%	-64.86%	360.51%	1,176.63%	1,641.05%	22.82%	25.35%
	250	224	236	431	43	24	23	147	149	151	147	149	158
Material Cost %	52%	50%	54%	80%	82%	70%	72%	42%	48%	51%	47%	36%	41%
Employee Cost %	13%	13%	13%	10%	18%	49%	77%	23%	21%	24%	21%	22%	21%
Other Expenses %	16%	15%	15%	20%	29%	81%	119%	42%	28%	24%	29%	30%	21%
Operating Profit	60	66	51	-37	-10	-12	-15	-9	4	1	4	21	33
OPM %	19%	23%	18%	-9%	-29%	-99%	-168%	-7%	2%	1%	3%	12%	17%
	6	7	7	25	11	13	14	4	15	18	28	2	8
Exceptional items				387				216			-6	-5	-0
Interest	20	21	21	-11	0	0	0	-27	1	2	1	-2	1
Depreciation	14	13	14	13	0	0	0	7	7	7	9	8	8
Profit before tax	32	39	24	373	1	1	-1	230	10	10	16	12	33
	18%	18%	18%	36%	-3%	32%		4%	16%	22%	24%	-26%	25%
Current tax	6	7	4	145	-0	0	-1	4	2	2	4	5	8
Deferred tax		0		-11				4	0			-8	-0
	17	32	19	239	1	0	0	222	9	8	10	15	25
Profit from associates	-0	-0	-0		-0	0	0	-0	0	-0	0	0	0
YOY Profit Growth %	-13.26%	24.91%	-29.38%		-94.57%	-98.69%	-99.97%	-6.95%	837.85%	1,833.27%	153,741.94%	-93.20%	181.32%
EPS in Rs	2.92	5.36	3.29	40.42	0.16	0.07	0.00	32.96	1.28	1.00	1.17	1.81	2.84
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	299	270	276	382	30	3	1	145	148	150	149	173	186
YOY Sales Growth %	10.12%	-6.00%	-8.64%	31.41%	-89.81%	-99.00%	-99.49%	-62.08%	385.93%	5,458.99%	10,516.55%	19.31%	25.74%
	239	207	222	309	35	15	10	158	145	148	144	152	153
Material Cost %	51%	48%	53%	51%	83%	18%	26%	48%	48%	51%	47%	38%	40%
Employee Cost %	13%	13%	13%	10%	18%	193%	438%	21%	22%	24%	21%	22%	21%
Other Expenses %	16%	15%	15%	20%	14%	332%	262%	40%	28%	23%	28%	29%	21%
Operating Profit	60	63	54	73	-5	-12	-9	-13	3	2	5	20	33
OPM %	20%	23%	19%	19%	-15%	-443%	-626%	-9%	2%	1%	4%	12%	18%
	6	7	7	25	11	13	14	4	15	18	28	2	8
Exceptional items				387				216			-6	-5	-0
Interest	20	21	21	-11	0	0	0	-27	1	2	1	-2	1
Depreciation	14	13	14	13	0	0	0	7	7	7	9	8	8
Profit before tax	31	36	26	483	6	0	5	226	10	11	18	12	32
	17%	17%	18%	28%				4%	17%	21%	23%	-27%	25%
Current tax	5	6	5	144				4	2	2	4	5	8
Deferred tax		0		-11				4	0			-8
	17	30	22	350	6	0	5	218	8	9	11	15	24
YOY Profit Growth %	-15.34%	25.28%	-25.89%		-63.71%	-98.94%	-78.59%	-37.62%	31.22%	2,637.36%	131.68%	-93.15%	201.05%
EPS in Rs	2.89	5.09	3.66	59.17	1.05	0.05	0.78	32.34	1.18	1.10	1.32	1.79	2.81
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	765	765	757	780	1,039	1,207	1,281	562	641	665
YOY Sales Growth %			-1.16%	3.05%	33.23%	16.23%	6.10%	-56.15%	14.17%
	632	632	620	635	842	978	1,027	581	596	605
Material Cost %	51%	51%	53%	51%	51%	54%	52%	51%	44%	43%
Employee Cost %	12%	12%	12%	13%	11%	11%	12%	21%	22%	22%
Other Expenses %	19%	19%	17%	17%	19%	15%	17%	31%	27%	26%
Operating Profit	134	134	136	144	196	229	254	-19	45	60
OPM %	17%	17%	18%	19%	19%	19%	20%	-3%	7%	9%
	18	18	27	33	43	34	45	81	47	55
Exceptional items	-1	-1	83			-27	387	223	-11	-11
Interest	28	28	83	107	96	92	51	3	1	1
Depreciation	87	87	104	90	131	57	53	24	31	32
Profit before tax	36	36	59	-20	13	87	582	258	49	71
	39%	39%	35%		117%	45%	26%	3%	16%	16%
Current tax	3	3	4	0	6	15	162	3	13
Deferred tax	11	11	17	1	9	23	-11	4	-5
	22	22	38	-21	-2	48	421	250	41	57
Profit from associates						-0		-0	0	0
YOY Profit Growth %			75.37%	-155.12%			785.47%	-40.57%	-83.47%
EPS in Rs	4.86	4.86	10.28	-4.28	-0.36	8.06	71.24	37.25	4.95	6.82

Compounded Sales Growth

5 Years:: -4%
3 Years:: -19%
TTM:: 113%

Compounded Profit Growth

3 Years:: -5%
TTM:: -75%

Stock Price CAGR

5 Years:: 42%
3 Years:: 58%
1 Year:: 243%

Return on Equity

4 Years:: 27%
Last Year:: 3%

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	731	731	724	752	857	988	1,152	1,227	550	636	659
YOY Sales Growth %			-0.94%	3.78%	13.93%	15.35%	16.58%	6.54%	-55.22%	15.69%
	605	605	589	610	676	794	930	977	563	590	597
Material Cost %	51%	51%	52%	50%	50%	49%	54%	51%	52%	45%	44%
Employee Cost %	12%	12%	13%	13%	12%	11%	12%	12%	21%	21%	22%
Other Expenses %	19%	19%	17%	17%	17%	20%	16%	17%	30%	27%	25%
Operating Profit	126	126	135	142	180	194	222	250	-13	46	61
OPM %	17%	17%	19%	19%	21%	20%	19%	20%	-2%	7%	9%
	18	18	37	36	23	42	33	45	81	47	55
Exceptional items	-1	-1	83			-2	-27	387	223	-11	-11
Interest	28	28	83	107	100	96	92	51	3	1	1
Depreciation	87	87	104	90	87	131	57	53	24	31	31
Profit before tax	29	29	68	-20	16	8	79	577	264	50	73
	38%	38%	30%		127%	171%	46%	29%	3%	15%	15%
Current tax			3		11	5	13	161	4	13
Deferred tax	11	11	17	1	9	9	24	9	4	-5
	18	18	48	-21	-4	-6	42	418	256	43	59
YOY Profit Growth %			172.77%	-143.24%				885.09%	-38.79%	-83.38%
EPS in Rs	3.91	3.91	10.28	-4.20	-0.74	-0.97	7.19	70.81	38.08	5.09	7.02

Compounded Sales Growth

5 Years:: -6%
3 Years:: -18%
TTM:: 122%

Compounded Profit Growth

3 Years:: 0%
TTM:: -75%

Stock Price CAGR

5 Years:: 42%
3 Years:: 58%
1 Year:: 243%

Return on Equity

4 Years:: 27%
Last Year:: 3%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	60	67	69	87
Reserves	622	745	1,104	1,297
	862	217	33	18
Long term borrowings	753	199	26	12
Short term borrowings	109	18	7	6
	280	432	232	271
Trade payables	204	293	110	146
Minority interest		-0	-0	-0
Current liabilities	371	433	221	257
Total Liabilities	1,824	1,460	1,438	1,673
	594	231	266	305
Gross block	1,340	529	574	629
Accumulated depreciation	746	298	308	324
Goodwill & intangibles		11	11	27
CWIP	9	66	19	42
	1,222	1,163	1,154	1,327
Inventories	439	75	114	148
Trade receivables	505	313	165	199
Cash & equivalents	18	478	425	430
Current assets	1,165	959	865	977
Total Assets	1,824	1,460	1,438	1,673

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	195	-187	-29	-68
Profit for the year	48	539	250	43
Working capital changes	-51	-569	-20	-103
Direct taxes paid			-7	-7
	-13	-27	-113	-73
Fixed assets purchased	-13	-73	-64	-88
Fixed assets sold	0	10	39	1
	-186	657	72	142
Proceeds from borrowings		725	28
Repayment of borrowings	-46	-742	-7	-15
Interest paid	-129	-189	-42	-5
Net Cash Flow	-4	443	-69	1
Free Cash Flow	182	-260	-93	-156

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	7.0%	72.1%	25.2%	3.4%
ROCE	—	11.9%	67.7%	21.3%	3.6%
Operating margin	—	15.0%	14.2%	-7.4%	-0.8%
Net margin	—	3.9%	31.5%	44.6%	6.9%
Debt / equity	—	1.26	0.27	0.03	0.01
Current ratio	—	3.14	2.22	3.92	3.80
Debtor days	—	153	67	107	116
Inventory days	—	209	27	123	156
Days payable	—	97	107	119	154
Cash conversion cycle	—	265	-13	111	118
Working capital days	—	240	112	419	420

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 42.93%
FIIs 10.78%
DIIs 0.20%
Public 46.09%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	42.00%	42.00%	42.00%	42.00%	42.00%	40.94%	40.94%	39.50%	39.50%	42.99%	42.93%	42.93%
	0.31%	0.25%	1.26%	0.65%	0.46%	3.07%	4.27%	14.80%	14.33%	13.88%	10.70%	10.78%
Foreign portfolio investors (Cat. I)	0.31%	0.25%	1.13%	0.49%	0.46%	3.06%	4.09%	14.80%	14.33%	13.42%	8.24%	8.62%
Foreign portfolio investors (Cat. II)		0.01%	0.14%	0.16%		0.01%	0.18%			0.46%	2.46%	2.16%
	18.73%	8.03%	0.94%	0.94%	0.94%	0.91%	0.91%	0.68%	0.68%		0.17%	0.20%
Alternative investment funds	18.73%	8.03%	0.94%	0.94%	0.94%	0.91%	0.91%	0.68%	0.68%		0.17%	0.20%
	38.95%	49.72%	55.80%	56.41%	56.60%	55.07%	53.87%	45.02%	45.50%	43.12%	46.20%	46.09%
Retail (up to ₹2 lakh)	15.59%	14.14%	16.44%	16.69%	17.19%	16.24%	17.14%	15.44%	15.33%	13.07%	13.75%	13.56%
HNIs (above ₹2 lakh)	13.68%	16.32%	20.25%	19.94%	20.92%	21.37%	24.22%	19.52%	19.74%	19.84%	20.70%	21.84%
NRIs	0.38%	0.33%	0.39%	0.71%	0.70%	0.92%	2.55%	2.06%	2.34%	2.18%	2.25%	2.33%
Bodies corporate	7.87%	16.86%	16.49%	16.50%	15.13%	13.99%	7.10%	5.64%	5.73%	5.69%	7.12%	6.24%
IEPF	0.26%	0.26%	0.26%	0.26%	0.26%	0.25%	0.25%	0.27%	0.27%	0.26%	0.26%	0.26%
No. of Shareholders	24,633	22,439	25,461	28,883	28,752	28,117	28,709	43,780	42,121	39,222	40,881	42,667

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 20 Sep 2011
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

Ind-Swift Laboratories INDSWFTLAB: Essix Biosciences Warrant ConversionKalkine India · 4 d ago

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Ind-Swift Laboratories Limited

What is the share price of Ind-Swift Laboratories Limited today?

Ind-Swift Laboratories Limited (INDSWFTLAB) last traded at ₹359.25 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Ind-Swift Laboratories Limited?

About ₹3,174 crore at the latest price.

What is the P/E ratio of Ind-Swift Laboratories Limited?

About 53.7 times its earnings over the last 12 months.

Is Ind-Swift Laboratories Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Ind-Swift Laboratories Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Ind-Swift Laboratories Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Ind-Swift Laboratories Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Ind-Swift Laboratories Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next